Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track

05/19

BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.

The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.

Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1172120087"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172120087\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172120087?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172120087","market":"sg","top_or_hot":-1,"title":"Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval","media":"Stock Track","content":"<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-19 10:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1172120087","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172120087","pubTimestamp":1779159162,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物"},"translate_title":"个股赛道|博安生物盘中大涨14.97%因股份回购计划及澳门药物获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}